Gilead Sciences Inc (GILD)

62.34
-0.02(-0.03%)
After Hours
62.20
-0.14(-0.22%)
- Real-time Data
  • Volume:
    5,026,631
  • Day's Range:
    61.36 - 62.47
  • 52 wk Range:
    57.17 - 74.12

GILD Overview

Prev. Close
62.36
Day's Range
61.36-62.47
Revenue
27.47B
Open
61.9
52 wk Range
57.17-74.12
EPS
3.58
Volume
5,026,631
Market Cap
78.19B
Dividend (Yield)
2.92
(4.68%)
Average Volume (3m)
7,933,482
P/E Ratio
17.42
Beta
0.39
1-Year Change
-10.04%
Shares Outstanding
1,254,313,448
Next Earnings Date
26 Jul 2022
What is your sentiment on Gilead?
or
Market is currently closed. Voting is open during market hours.

Gilead Sciences Inc News

Gilead Sciences Inc Analysis

Gilead Sciences Inc Company Profile

Gilead Sciences Inc Company Profile

Employees
14400

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. It sells and distributes its products in the United States through the wholesale channel. It operates in more than 35 countries worldwide.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
  • Good job GILD. bullish move forward
    0
    • Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
      1
      • Up Again
        0
        • Time to load up before the big rise coming next week
          3
          • Classic pump n’ dump. What a shambles
            1
            • Will reach above 95
              5
              • when? hahah
                0
            • Good time to accumulate.
              1
              • Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
                2
                • High chance to be trading above 90, good long stock
                  4
                  • By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
                    3